Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs

References

• Moraes-Filho JP, Navarro-Rodriguez T, Barbuti R, Eisig J, Chinzon D, Bernardo W; Brazilian Gerd Consensus Group. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq. Gastroenterol. 47(1), 99–115 (2010).
   PubMedGoogle Scholar
• Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101(8), 1900–1920 (2006).
   PubMed Web of Science ®Google Scholar
• Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de Práctica Clínica. Actualización 2007. Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2007. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1.
   Google Scholar
• Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54(5), 710–717 (2005).
   PubMed Web of Science ®Google Scholar
• Moshkowitz M, Horowitz N, Halpern Z, Santo E. Gastroesophageal reflux disease symptoms: prevalence, sociodemographics and treatment patterns in the adult Israeli population. World J. Gastroenterol. 17(10), 1332–1335 (2011).
   Google Scholar
• Ponce J, Vegazo O, Beltrán B et al.; Iberge Study Group. Prevalence of gastro–oesophageal reflux disease in Spain and associated factors. Aliment. Pharmacol. Ther. 23(1), 175–184 (2006).
   PubMed Web of Science ®Google Scholar
• Saritas Yuksel E, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: cough, asthma, laryngitis, chest pain. Swiss Med. Wkly. 142, w13544 (2012).
   Google Scholar
• Gisbert JP, Cooper A, Karagiannis D et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual. Life Outcomes 7, 90 (2009).
   PubMedGoogle Scholar
• Nicholson A, Jankowski J. Acid reflux and oesophageal cancer. Recent Results Cancer Res. 185, 65–82 (2011).
   PubMedGoogle Scholar
• Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment. Pharmacol. Ther. 28(9), 1134–1139 (2008).
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Nishino M, Kodaira C et al. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J. Clin. Pharmacol. 50(3), 320–330 (2010).
   Google Scholar
• Cryer B, Spechler S. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on acid reflux in patients with gastroesophageal reflux disease (GERD). Presented at: Program and Abstracts of Digestive Disease Week. San Diego, CA, USA, 21–24 May 2000 (Abstract 4796).
   Google Scholar
• Bhatt DL, Scheiman J, Abraham NS et al.; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118(18), 1894–1909 (2008).
   PubMed Web of Science ®Google Scholar
• Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA. Impact of compliance with proton pump inhibitors on NSAID treatment. Am. J. Manag. Care 15(10), 681–688 (2009).
   Google Scholar
• Chen JT, Pucino F, Resman-Targoff BH. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations? J. Pain Palliat. Care Pharmacother. 20(4), 11–32 (2006).
   Google Scholar
• Thiéfin G, Schaeverbeke T, Barthélémy P, Soufflet C, Flipo RM. Upper gastrointestinal symptoms in patients treated with nonsteroidal anti-inflammatory drugs: prevalence and impact – the COMPLAINS study. Eur. J. Gastroenterol. Hepatol. 22(1), 81–87 (2010).
   PubMed Web of Science ®Google Scholar
• Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the Health-Related Quality of Life score and physiologic parameters. Am. Surg. 64(7), 649–653 (1998).
   PubMedGoogle Scholar
• Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J. Am. Coll. Surg. 183(3), 217–224 (1996).
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 9, 38 (2011).
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 24(2), 121–132 (2010).
   PubMed Web of Science ®Google Scholar
• Helsper CW, Smeets HM, Numans ME, Knol MJ, Hoes AW, de Wit NJ. Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Pharmacoepidemiol. Drug Saf. 18(9), 800–806 (2009).
   PubMed Web of Science ®Google Scholar
• Suh DC, Hunsche E, Shin HC, Mavros P. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology (Oxford) 47(4), 458–463 (2008).
   Google Scholar
• Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am. J. Gastroenterol. 103(11), 2908–2918 (2008).
   PubMed Web of Science ®Google Scholar
• Burmester G, Lanas A, Biasucci L et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European Expert Panel. Ann. Rheum. Dis. 70(5), 818–822 (2011).
   PubMed Web of Science ®Google Scholar
• Lanas A, Muñoz M, Caballero Correa M, Martínez Jiménez P; investigadores del estudio GAP. Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study. Gastroenterol. Hepatol. 33(2), 80–91 (2010).
   PubMedGoogle Scholar
• Doherty GA, Cannon MD, Lynch KM et al. Co-prescription of gastro-protectants in hospitalized patients: an analysis of what we do and what we think we do. J. Clin. Gastroenterol. 44(3), e51–e56 (2010).
   Google Scholar
• van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin. Gastroenterol. Hepatol. 7(8), 855–861 (2009).
   Google Scholar
• Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment. Pharmacol. Ther. 30(7), 767–774 (2009).
   PubMed Web of Science ®Google Scholar
• Desai JC, Sanyal SM, Goo T et al. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig. Dis. Sci. 53(8), 2059–2065 (2008).
   Google Scholar
• Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002. BMC Gastroenterol. 9, 25 (2009).
   PubMedGoogle Scholar